This pilot trial studies how well a hepatobiliary iminodiacetic acid (HIDA) scan works in studying liver function in participants with liver cancer undergoing yttrium Y-90 therapy. Imaging techniques such as HIDA may help the investigators to establish whether there is a relationship between yttrium Y-90 distribution to non-tumoral (normal) liver tissue and the incidence and severity of yttrium Y-90 therapy-induced liver damage. This may improve the selection criteria and outcomes in populations selected for Y-90 therapy in the future.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT02966223.
PRIMARY OBJECTIVES:
I. Determine the difference in regional liver function between pre and 3 months post yttrium Y-90 (yttrium 90) delivery using the HIDA functional imaging scans.
SECONDARY OBJECTIVES:
I. Determine the difference in global liver function between pre and 3 months post yttrium 90 delivery using the HIDA functional imaging scans.
II. Determine the correlation between the differences in liver function (both regional and global) with the yttrium 90 (Y 90) dose provided.
OUTLINE:
Participants receive undergo HIDA scan for 30 minutes prior to, and 3 months after undergoing yttrium Y-90 therapy.
After completion of study treatment, participants are followed up at 6 and 12 months.
Lead OrganizationIndiana University/Melvin and Bren Simon Cancer Center
Principal InvestigatorMark Tann
